{"id":20154,"date":"2025-10-25T17:30:20","date_gmt":"2025-10-25T16:30:20","guid":{"rendered":"https:\/\/drugprevent.org.uk\/ppp\/?p=20154"},"modified":"2026-01-11T18:02:27","modified_gmt":"2026-01-11T17:02:27","slug":"high-concentration-delta-9-tetrahydrocannabinol-cannabis-products-and-mental-health-outcomes-a-systematic-review","status":"publish","type":"post","link":"https:\/\/drugprevent.org.uk\/ppp\/2025\/10\/high-concentration-delta-9-tetrahydrocannabinol-cannabis-products-and-mental-health-outcomes-a-systematic-review\/","title":{"rendered":"High-Concentration Delta-9-Tetrahydrocannabinol Cannabis Products and Mental Health Outcomes : A Systematic Review"},"content":{"rendered":"

 <\/p>\n

NIH – National Library of Medicine – National Center for Biotechnology Information<\/span><\/strong><\/span><\/p>\n

\n
\n
\n
2025 Oct;178(10):1429-1440.<\/span><\/div>\n

doi: 10.7326\/ANNALS-24-03819.<\/span>\u00a0Epub 2025 Aug 26.<\/span><\/span><\/div>\n<\/div>\n<\/header>\n

by Thanitsara Rittiphairoj1<\/sup>,\u00a0<\/span><\/span>Louis Leslie2<\/sup>,\u00a0<\/span><\/span>Jean-Pierre Oberste2<\/sup>,\u00a0<\/span><\/span>Tsz Wing Yim2<\/sup>,\u00a0<\/span><\/span>Gregory Tung3<\/sup>,\u00a0<\/span><\/span>Lisa Bero4<\/sup>,\u00a0<\/span><\/span>Paula Riggs5<\/sup>,\u00a0<\/span><\/span>Kent Hutchison6<\/sup>,\u00a0<\/span><\/span>Jonathan Samet7<\/sup>,\u00a0<\/span><\/span>Tianjing Li8<\/sup><\/span><\/h1>\n
\n

Abstract<\/span><\/h2>\n
\n

Background:\u00a0<\/strong>Rapid changes in the legalized cannabis market have led to the predominance of high-concentration delta-9-tetrahydrocannabinol (THC) cannabis products.<\/span><\/p>\n

Purpose:\u00a0<\/strong>To systematically review associations of high-concentration THC cannabis products with mental health outcomes.<\/span><\/p>\n

Data sources:\u00a0<\/strong>Ovid MEDLINE through May 2025; EMBASE, Allied and Complementary Medicine Database, Cochrane Library, Database of Abstracts of Reviews of Effects, CINAHL, and Toxicology Literature Online through August 2024.<\/span><\/p>\n

Study selection:\u00a0<\/strong>Two reviewers independently selected studies with high-concentration THC defined as greater than 5 mg or greater than 10% THC per serving or labeled as “high-potency concentrate,” “shatter,” or “dab.”<\/span><\/p>\n

Data extraction:\u00a0<\/strong>Outcomes included anxiety, depression, psychosis or schizophrenia, and cannabis use disorder (CUD). Results were categorized by association direction and by study characteristics. Therapeutic studies were defined by use of cannabis to treat medical conditions or symptoms.<\/span><\/p>\n

Data synthesis:\u00a0<\/strong>Ninety-nine studies (221 097 participants) were included: randomized trials (42%), observational studies (47%), and other interventional study designs (11%); more than 95% had moderate or high risk of bias. In studies not testing for therapeutic effects, high-concentration THC products showed consistent unfavorable associations with psychosis or schizophrenia (70%) and CUD (75%). No therapeutic studies reported favorable results for psychosis or schizophrenia. For anxiety and depression, 53% and 41% of nontherapeutic studies, respectively, reported unfavorable associations, especially among healthy populations. Among therapeutic studies, nearly half found benefits for anxiety (47%) and depression (48%), although some also found unfavorable associations (24% and 30%, respectively).<\/span><\/p>\n

Limitation:\u00a0<\/strong>Moderate and high risk of bias of individual studies and limited evaluation of contemporary products.<\/span><\/p>\n

Conclusion:\u00a0<\/strong>High-concentration THC products are associated with unfavorable mental health outcomes, particularly for psychosis or schizophrenia and CUD. There was some low-quality evidence, inconsistent by population, for therapeutic benefits for anxiety and depression.<\/span><\/p>\n

Primary funding source:\u00a0<\/strong>Colorado General Assembly, House Bill 21-1317<\/span><\/p>\n

Source: https:\/\/pubmed.ncbi.nlm.nih.gov\/40854216\/<\/span><\/strong><\/span><\/p>\n

 <\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

  NIH – National Library of Medicine – National Center for Biotechnology Information 2025 Oct;178(10):1429-1440. doi: 10.7326\/ANNALS-24-03819.\u00a0Epub 2025 Aug 26. by Thanitsara Rittiphairoj1,\u00a0Louis Leslie2,\u00a0Jean-Pierre Oberste2,\u00a0Tsz Wing Yim2,\u00a0Gregory Tung3,\u00a0Lisa Bero4,\u00a0Paula Riggs5,\u00a0Kent Hutchison6,\u00a0Jonathan Samet7,\u00a0Tianjing Li8 Abstract Background:\u00a0Rapid changes in the legalized cannabis market have led to the predominance of high-concentration delta-9-tetrahydrocannabinol (THC) cannabis products. Purpose:\u00a0To systematically review […]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[30,68,22,64,120,139,19],"tags":[],"class_list":["post-20154","post","type-post","status-publish","format-standard","hentry","category-cannabis-marijuana","category-drug-use-various-effects","category-effects-of-drugs-papers","category-health","category-mental-health","category-strategy-and-policy","category-usa"],"_links":{"self":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts\/20154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/comments?post=20154"}],"version-history":[{"count":1,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts\/20154\/revisions"}],"predecessor-version":[{"id":20155,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts\/20154\/revisions\/20155"}],"wp:attachment":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/media?parent=20154"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/categories?post=20154"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/tags?post=20154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}